Intelligent Bio Solutions Stock Today

INBS Stock  USD 1.77  0.06  3.28%   

Performance

OK

 
Weak
 
Strong

Odds Of Distress

Below Average

 
High
 
Low
Intelligent Bio is selling for under 1.77 as of the 13th of July 2025; that is 3.28% down since the beginning of the trading day. The stock's lowest day price was 1.75. Intelligent Bio has about a 43 percent probability of financial distress in the next few years of operation but had a somewhat ok performance during the last 90 days. The performance scores are derived for the period starting the 13th of June 2025 and ending today, the 13th of July 2025. Click here to learn more.
Business Domain
Health Care Equipment & Services
IPO Date
23rd of December 2020
Category
Healthcare
Classification
Health Care
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd. Intelligent Bio operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 6.91 M outstanding shares of which 536.98 K shares are currently shorted by private and institutional investors with about 3.76 trading days to cover. More on Intelligent Bio Solutions

Moving together with Intelligent Stock

  0.83DH Definitive HealthcarePairCorr
  0.79FIGS Figs IncPairCorr

Moving against Intelligent Stock

  0.79FEMY FemasysPairCorr
  0.76GCTK GlucoTrackPairCorr
  0.74ELV Elevance Health Earnings Call This WeekPairCorr
  0.73MOH Molina HealthcarePairCorr
  0.68TFX Teleflex IncorporatedPairCorr
  0.65CNC Centene CorpPairCorr

Intelligent Stock Highlights

President CEOHarry Simeonidis
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Diagnostics & Research, Healthcare (View all Sectors)
Average Analyst Recommendation
Debt Levels
Intelligent Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Intelligent Bio's financial leverage. It provides some insight into what part of Intelligent Bio's total assets is financed by creditors.
Liquidity
Intelligent Bio Solutions currently holds 871.44 K in liabilities. Intelligent Bio Solutions has a current ratio of 2.28, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Intelligent Bio's use of debt, we should always consider it together with its cash and equity.

Net Income

(9.63 Million)
Intelligent Bio Solutions (INBS) is traded on NASDAQ Exchange in USA. It is located in 135 West, 41ST Street, New York, NY, United States, 10036 and employs 50 people. Intelligent Bio is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.23 M. Intelligent Bio Solutions conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 6.91 M outstanding shares of which 536.98 K shares are currently shorted by private and institutional investors with about 3.76 trading days to cover. Intelligent Bio Solutions currently holds about 8.28 M in cash with (9.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56.
Check Intelligent Bio Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Intelligent Bio is $12.23 Million. Roughly 85.83 (percent) of Intelligent Bio outstanding shares are held by general public with 1.37 % owned by insiders and only 12.8 pct. by outside corporations. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Intelligent Ownership Details

Intelligent Stock Institutional Holders

InstituionRecorded OnShares
Tower Research Capital Llc2025-03-31
0.0
Two Sigma Securities, Llc2025-03-31
0.0
Alyeska Investment Group, L.p.2025-03-31
613.9 K
Altium Capital Management, Lp2025-03-31
149.3 K
Geode Capital Management, Llc2025-03-31
49 K
Susquehanna International Group, Llp2025-03-31
35.5 K
Vanguard Group Inc2025-03-31
15.5 K
Goldman Sachs Group Inc2025-03-31
12.8 K
Ubs Group Ag2025-03-31
1.2 K
Bank Of America Corp2025-03-31
45.0
Sbi Securities Co Ltd2025-03-31
1.0
View Intelligent Bio Diagnostics

Intelligent Bio Historical Income Statement

At this time, Intelligent Bio's Depreciation And Amortization is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 11.2 M in 2025, whereas EBIT is likely to drop (9.5 M) in 2025. View More Fundamentals

Intelligent Stock Against Markets

Intelligent Bio Corporate Management

BBus CAChief OfficerProfile
Alex ArzenoVP RelationsProfile
Victoria GavrilenkoOperations ManagerProfile
Anna TurkingtonVice MarketingProfile
Callistus SequeiraVice OperationsProfile
Doug HeathVice SalesProfile

Additional Tools for Intelligent Stock Analysis

When running Intelligent Bio's price analysis, check to measure Intelligent Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intelligent Bio is operating at the current time. Most of Intelligent Bio's value examination focuses on studying past and present price action to predict the probability of Intelligent Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intelligent Bio's price. Additionally, you may evaluate how the addition of Intelligent Bio to your portfolios can decrease your overall portfolio volatility.